Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
332
datasets available to search
ShareScore release 0.9.0
Dataset results
332 results for “Cardiac failure”
Dataset related to: The Impact of Cardiac Rehabilitation on Activities of Daily Life in Elderly Patients With Heart Failure
<p>Dataset related to the article:</p> <p>Paneroni M, Scalvini S, Corrà U, Lovagnini M, Maestri R, Mazza A, Raimondo R, Agostoni P, La Rovere MT. The Impact of Cardiac Rehabilitation on Activities of Daily Life in Elderly Patients With Heart Failure. Front Physiol. 2022;12:785501. doi: 10.3389/fphys.2021.785501.</p> <p><strong>Background:</strong> In elderly chronic heart failure (HF) patients, activities of daily living (ADLs) require the use of a high proportion of patients' peak aerobic capacity, heart rate, and ventilation. <strong>Objectives:</strong> To assess the effects of short-term comprehensive cardiac rehabilitation (CR) on the metabolic requirement of ADLs in elderly patients with chronic HF. <strong>Methods:</strong> The study population comprised 99 elderly chronic HF patients (mean age 72 ± 5 years, 80% male, 61% ejection fraction <40%, mean NT-proBNP 2,559 ± 4,511 pg/ml) participating in a short-term (mean days 19 ± 7) residential CR program. Before and after CR, participants, while wearing a portable ergospirometer, performed a standardized ADL battery: ADL1 (getting dressed), ADL2 (folding 8 towels), ADL3 (putting away 6 bottles), ADL4 (making a bed), ADL5 (sweeping the floor for 4 min), ADL6 (climbing 1 flight of stairs carrying a 1.5 Kg load), and ADL7 (a standard 6-min walking test). <strong>Results:</strong> After CR, task-related oxygen uptake did not change in any of the domestic ADLs. Notably, there was a significant decrease in the cumulative time required to perform ADLs (ADL 1-4 and ADL6; from 412 ± 147 to 388 ± 141 s, <em>p</em> = 0.001) and a reduction in maximal heart rate in ADL1 and 3 (<em>p</em> = 0.005 and <em>p</em> = 0.027, respectively). Changes occurred in the 6MWT with an increase in oxygen uptake (<em>p</em> = 0.005) and in the distance covered (<em>p</em> < 0.001) and a significant decrease in the Borg scale of dyspnea (<em>p</em> = 0.004). <strong>Conclusion:</strong> Elderly patients with chronic heart failure who are engaged in a short-term residential CR program improve the performance of routine ADLs.</p>
Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension [Affymetrix]
GEO Series GSE154321. Mus musculus. 11 samples. Type: Expression profiling by array.
Loss of mitochondrial pyruvate transport initiates cardiac glycogen accumulation and heart failure
GEO Series GSE268694. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension
GEO Series GSE154327. Mus musculus; Rattus norvegicus. 33 samples. Type: Expression profiling by array.
Cardiac hypertrophy and failure
GEO Series GSE2355. Mus musculus. 32 samples. Type: Expression profiling by array.
changes in cardiac transcription profiles brought about by heart failure
GEO Series GSE1145. Homo sapiens. 107 samples. Type: Expression profiling by array.
Smilax glabra Roxb exerts protective effect on cardiac and mitochondrial function in heart failure rats induced by doxorubicin
Open the record for dataset details and reuse information.
Dataset related to article: "Diffuse idiopathic skeletal hyperostosis in subjects with congestive heart failure undergoing cardiac rehabilitation: A decision tree analysis"
<p>We provide the raw data used for the following article:</p> <ul> <li> <p>Ambrosino P, Scrutinio D, De Campi M, Miniero E, Formisano R, Spedicato GA, Iannuzzi GL, Pappone N.<br> <em>Diffuse idiopathic skeletal hyperostosis in subjects with congestive heart failure undergoing cardiac rehabilitation: A decision tree analysis. </em><br> "J Rehabil Med". 2020 Mar 18;52(3):jrm00030. doi: 10.2340/16501977-2658. PMID: 32104899.</p> </li> </ul> <p> </p> <p><strong>Abstract</strong></p> <p><strong>Objective: </strong> To assess the prevalence of diffuse idiopathic skeletal hyperostosis and its relationship with vascular risk factors among patients with congestive heart failure.</p> <p><strong>Design: </strong> Population-based cross-sectional study.</p> <p><strong>Participants: </strong> A total of 584 consecutive patients admitted to a Rehabilitative Cardiology Unit.</p> <p><strong>Methods: </strong> Chi-square Automatic Interaction Detector (CHAID) decision tree analysis was used to build a predictive model.</p> <p><strong>Results: </strong> The mean age (standard deviation) of the study population was 68.1 years (standard deviation 12.3), and 77.7% of the subjects were men. The overall prevalence of diffuse idiopathic skeletal hyperostosis in the cohort was 49.8%. Logistic regression analysis showed that age was a predictor of diffuse idiopathic skeletal hyperostosis (odds ratio: 1.034; 95% confidence interval 1.021-1.047, p < 0.001), with increasing odds ratios for increasing age tertiles. The CHAID prediction model identified 2 age "buckets": < 69 and ≥ 69 years. Patients ≥ 69 years had a diffuse idiopathic skeletal hyperostosis prevalence of 60.1%, compared with 39.2% among those < 69 years. Notably, body mass index was a predictor of diffuse idiopathic skeletal hyperostosis in this younger subset of patients (p = 0.028), with 2 body mass index "buckets", ≤ 23.3 and > 23.3 kg/m2, the latter showing more than twice the prevalence of diffuse idiopathic skeletal hyperostosis (43.2% vs 20%).</p> <p><strong>Conclusion: </strong> Diffuse idiopathic skeletal hyperostosis is extremely frequent among patients with congestive heart failure, with age and body mass index being the strongest predictors.</p>
Dataset related to the article "Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan"
<p>This record contains raw data related to the article "Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan".</p> <p>Abstract: In terms of sacubitril/valsartan (S/V)-induced changes in heart failure with reduced ejection fraction (HFrEF) via three-dimensional (3D) transthoracic echocardiography (TTE) and S/V effects based on HF aetiology, data are lacking. We prospectively enrolled 51 HFrEF patients (24 ischaemic, 27 non-ischaemic). At baseline and at 6-month follow-up (6MFU) after S/V treatment<br> optimisation, we assessed the N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac remodelling by two-dimensional (2D) and 3DTTE. In non-ischaemic patients, 2D and 3DTTE showed an improvement in left ventricular (LV) size and biventricular function at 6MFU vs. baseline: 3D-LV end-diastolic volume (EDV) 103 ± 30 vs. 125 ± 32 mL/m2 (p < 0.05), 3D-LV ejection<br> fraction (EF) 40 ± 9 vs. 32 ± 5% (p < 0.05), right ventricular (RV) 3D-EF 48.4 ± 6.5 vs. 44.3 ± 7.5% (p < 0.05); only the 3D method detected RV size reduction: 3D-RVEDV 63 ± 27 vs. 71 ± 30 mL/m2 (p < 0.05). In ischaemic patients, only 3DTTE showed biventricular size and LV function improvement: 3D-LVEDV 112 ± 29 vs. 121 ± 27 mL/m2 (p < 0.05), 3D-LVEF 35 ± 6 vs. 32 ± 5% (p < 0.05), 3D-RVEDV 57 ± 11 vs. 63 ± 14 mL/m2 (p < 0.05); RV function did not ameliorate. In both ischaemic and nonischaemic<br> patients, diastolic function and NT-proBNP significantly improved. In HFrEF patients treated with S/V, 3DTTE helps to ascertain subtle changes in heart chambers’ size and function, which have a major impact on HFrEF prognosis. S/V has significantly different effects on LV function in non-ischaemic vs. ischaemic patients.</p>
Raw data for "The importance of re-evaluating the risk score in heart failure patients: An analysis from the Metabolic Exercise Cardiac Kidney Indexes (MECKI) score database" 2023 Int J Cardiol
<p>Abstract</p> <p><strong>Background: </strong>The role of risk scores in heart failure (HF) management has been highlighted by international guidelines. In contrast with HF, which is intrinsically a dynamic and unstable syndrome, all its prognostic studies have been based on a single evaluation. We investigated whether time-related changes of a well-recognized risk score, the MECKI score, added prognostic value. MECKI score is based on peak VO<sub>2</sub>, VE/VCO<sub>2</sub> slope, Na<sup>+</sup>, LVEF, MDRD and Hb.</p> <p><strong>Methods: </strong>A multi-centre retrospective study was conducted involving 660 patients who performed MECKI re-evaluation at least 6 months apart. Based on the difference between II and I evaluation of MECKI values (MECKI II - MECKI I = ∆ MECKI) the study population was divided in 2 groups: those presenting a score reduction (∆ MECKI <0, i.e. clinical improvement), vs. patients presenting an increase (∆ MECKI >0, clinical deterioration).</p> <p><strong>Results: </strong>The prognostic value of MECKI score is confirmed also when re-assessed during follow-up. The group with improved MECKI (366 patients) showed a better prognosis compared to patients with worsened MECKI (294 patients) (p < 0.0001). At 1st evaluation, the two groups differentiated by LVEF, V<sub>E</sub>/VCO<sub>2</sub> slope and blood Na<sup>+</sup> concentration, while at 2nd evaluation they differentiated in all 6 parameters considered in the score. The patients who improved MECKI score, improved in all components of the score but hemoglobin, while patients who worsened the score, worsened all parameters.</p> <p><strong>Conclusions: </strong>This study shows that re-assessment of MECKI score identifies HF subjects at higher risk and that score improvement or deterioration regards several MECKI score generating parameters confirming the holistic background of HF.</p>
Defining cardiac functional recovery in end-stage heart failure at single cell resolution
GEO Series GSE226314. Homo sapiens. 32 samples. Type: Expression profiling by high throughput sequencing.
Cardiac output changes during exercise in heart failure patients: focus on mid-exercise.
<p>This dataset contains the raw data of the paper "Cardiac output changes during exercise in heart failure patients: focus on mid-exercise."</p> <p><strong>Aims: </strong>Peak exercise oxygen uptake (VO<sub>2</sub> ) and cardiac output (CO) are strong prognostic indexes in heart failure (HF) but unrelated to real-life physical activity, which is associated to submaximal effort.</p> <p><strong>Methods and results: </strong>We analysed maximal cardiopulmonary exercise test with rest, mid-exercise, and peak exercise non-invasive CO measurements (inert gas rebreathing) of 231 HF patients and 265 healthy volunteers. HF patients were grouped according to exercise capacity (peak VO<sub>2</sub> < 50% and ≥50% pred, Groups 1 and 2). To account for observed differences, data regarding VO<sub>2</sub> , CO, stroke volume (SV), and artero-venous O<sub>2</sub> content difference [ΔC(a-v)O<sub>2</sub> ] were adjusted by age, gender, and body mass index. A multiple regression analysis was performed to predict peak VO<sub>2</sub> from mid-exercise cardiopulmonary exercise test and CO parameters among HF patients. Rest VO<sub>2</sub> was lower in HF compared with healthy subjects; meanwhile, Group 1 patients had the lowest CO and highest ΔC(a-v)O<sub>2</sub> . At mid-exercise, Group 1 patients achieved a lower VO<sub>2</sub> , CO, and SV [0.69 (interquartile range 0.57-0.80) L/min; 5.59 (4.83-6.67) L/min; 62 (51-73) mL] than Group 2 [0.94 (0.83-1.1) L/min; 7.6 (6.56-9.01) L/min; 77 (66-92) mL] and healthy subjects [1.15 (0.93-1.30) L/min; 9.33 (8.07-10.81) L/min; 87 (77-102) mL]. Rest to mid-exercise SV increase was lower in Group 1 than Group 2 (P = 0.001) and healthy subjects (P < 0.001). At mid-exercise, ΔC(a-v)O<sub>2</sub> was higher in Group 2 [13.6 (11.8-15.4) mL/100 mL] vs. healthy patients [11.6 (10.4-13.2) mL/100 mL] (P = 0.002) but not different from Group 1 [13.6 (12.0-14.9) mL/100 mL]. At peak exercise, Group 1 patients achieved a lower VO<sub>2</sub> , CO, and SV than Group 2 and healthy subjects. ΔC(a-v)O<sub>2</sub> was the highest in Group 2. At multivariate analysis, a model comprising mid-exercise VO<sub>2</sub> , carbon dioxide production (VCO<sub>2</sub> ), CO, haemoglobin, and weight predicted peak VO<sub>2</sub> , P < 0.001. Mid-exercise VO<sub>2</sub> and CO, haemoglobin, and weight added statistically significantly to the prediction, P < 0.050.</p> <p><strong>Conclusions: </strong>Mid-exercise VO<sub>2</sub> and CO portend peak exercise values and identify severe HF patients. Their evaluation could be clinically useful.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.